Omnia Abd El-Fattah
Tanta University Hospital, Egypt
Title: Predictive value of PKM2 expression in advanced Non-Small Cell Lung Cancer patients (NSCLC) treated with front-line platinum-based chemotherapy
Biography
Biography: Omnia Abd El-Fattah
Abstract
Background: The aim of the study was, to assess the expression of pyruvate kinase isozymes M2 (PKM2) in advanced NSCLC patients treated with front-line platinum-based chemotherapy and analyze its predictive value on both progression free and overall survival.
Methods: 72 cases with histologically confirmed stage IIIB and IV NSCLC who were treated with front-line platinum-based chemotherapy. 32 NSCLC patients were treated with front-line non-platinum-based doublets were enrolled in this study (as control), immunohistochemical staining for PKM2 was evaluated.
Results: In Platinum group, the median OS (overall survival) was 7 vs. 19 months; PË‚0.001 for those patients with high compared to those with low expression respectively and the median PFS was 5 vs. 9 months; PË‚0.001 for those patients with high PKM2 expression compared to those with low expression respectively. In control group, there was no significant difference between high and low PKM2 expression as regard median OS (9 vs 10 months; P≤0.451) and median PFS progression-free survival (7 vs. 8 months; P=0.638). Conclusions: Our study proved that PKM2 expression may be a predictive biomarker of platinum sensitivity in advanced NSCLC patients treated with platinum-based chemotherapy.